Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team? Patients with MPN who had an AMI are analyzed for risk of additional major adverse cardiovascular events and bleeding. Do cytoreductive therapies affect quality of life for patients with MPN in different ways? Researchers evaluated risk factors for ATEs and VTEs. Their scoring system performed better than the current standard. The phase II study results are in. Researchers will now test rusfertide against placebo in a randomized clinical trial. Researchers determined the incidence of TEAEs related to rusfertide in patients with PV. Essential thrombocytosis (ET), polycythemia vera (PV), and primary myelofibrosis (PM) are BCR-ABL–negative ... According to Alexander Chan, MD, and colleagues from the Department of Pathology at the Memorial Sloan Kettering Cancer ... In patients with polycythemia vera (PV), arterial thrombosis (AT) and venous thrombosis (VT) events are common complications ... Polycythemia vera (PV) is subject to the chronic inflammation commonly observed in other myeloproliferative neoplasms. Recent ... In a follow-up to the randomized controlled trial APL0406, researchers compared long-term health-related quality of life of ... A phase I study tested low dose clofarabine with escalating doses of entinostat in adults with Philadelphia ... A study published in the Journal of Clinical Oncology found that therapy with two doses of imetelstat appears to have ... In an a study published in Leukemia Research, researchers trialed the combination of dociparstat sodium (DSTAT) and ... Findings from a report published in Blood Advances suggest that certain germline variants in DNA repair pathway genes, ... Anticoagulation with vitamin K antagonists (VKAs) such as warfarin has been the standard of care for thrombosis in patients ... In a case series published in the American Journal of Hematology, authors evaluated the relationship between ... A study recently published in the Journal of Clinical Nursing explored the experiences of daily living and identified ... In patients with myeloproliferative neoplasms (MPNs), presence of somatic mutations in the hematopoietic transcription factor ... Venetoclax combined with a hypomethylating agent (HMA) has emerged as an effective treatment regimen for acute myeloid ...